ARISING HEALTHALIVE. AWAKE. AWARE.Read the magazines →

← November 18, 2026 edited reader edition

THE ARISING · Longevity & Healthspan

No Clear Benefit for NAD+ Boosters in Small Heart Failure Trials

A pooled analysis found no reliable improvement in hospitalization, survival or the heart's pumping function.

A review pooled four randomized trials involving 387 adults with symptomatic heart failure. The trials tested intravenous NAD+ or oral nicotinamide riboside, which the body can use to make NAD+, against placebo. Participants were already receiving guideline-directed treatment.

Across three trials, the relative risk of heart failure hospitalization was 0.63 with the NAD+-related interventions compared with placebo (95% confidence interval 0.36 to 1.09). The estimate for all-cause mortality was even less precise: 0.51 (95% confidence interval 0.09 to 2.86) across two trials. Neither result established a benefit, and the review found no statistically significant improvement in left ventricular ejection fraction, a measure of how much blood the heart pumps out with each beat.

In two trials involving 209 patients, creatinine was on average 7.46 µmol/L higher with NAD+ (95% confidence interval 2.21 to 12.71). That is a laboratory safety signal to study, not proof of kidney injury.

These studies do not give patients a reason to add NAD+ products to standard heart failure treatment. Larger, longer trials would be needed to tell whether these interventions help or harm.

The uncertainty is important: the intervals around the results were wide enough to include both a meaningful benefit and no benefit. The review also grouped two distinct interventions, so its overall estimate is not evidence that either one works on its own. It did not test healthy adults who take NAD+ products for longevity.

Primary study: European Journal of Clinical Pharmacology

THE ARISING NEWSLETTER

Science moves forward.
Come with it.

Research, clear explanations, and a little room for wonder.
Read and follow The Arising on Substack.

Find The Arising on Substack ↗